Suppr超能文献

瑞舒伐他汀联合常规运动可维持辅酶 Q10 水平,并显著增加冠心病患者的高密度脂蛋白胆固醇。

Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.

机构信息

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

出版信息

Atherosclerosis. 2011 Jul;217(1):158-64. doi: 10.1016/j.atherosclerosis.2011.02.050. Epub 2011 Mar 10.

Abstract

BACKGROUND

Coenzyme Q10 levels are low in patients with coronary artery disease (CAD), and increasing or preserving coenzyme Q10 could be a beneficial strategy. Exercise and statins improve high-density lipoprotein cholesterol (HDL-C) levels. However, statins inhibit coenzyme Q10 biosynthesis, and the combination of statins with coenzyme Q10 supplementation increases HDL-C compared to statins alone. We compared the effects of two statins (rosuvastatin and atorvastatin) combined with exercise on coenzyme Q10 and HDL-C levels in CAD patients.

METHODS

After randomizing 28 CAD patients to rosuvastatin (n=14) and atorvastatin (n=14) groups, patients performed weekly in-hospital aerobic exercise and daily home exercise for 20 weeks. We measured serum lipids, ubiquinol, and exercise capacity.

RESULTS

Both statins equally improved exercise capacity and lowered low-density lipoprotein cholesterol and triglyceride levels. Rosuvastatin significantly increased HDL-C (rosuvastatin, +12 ± 9 mg/dL [+30%], atorvastatin, +5 ± 5 mg/dL [+13%], p=0.014) and apolipoprotein A1 (ApoA1) (rosuvastatin, +28.3 ± 20.7 mg/dL, atorvastatin, +13.4 ± 12.0 mg/dL, p=0.030) compared to atorvastatin. Atorvastatin significantly decreased serum ubiquinol (731 ± 238 to 547 ± 219 nmol/L, p=0.001), but rosuvastatin (680±233 to 668 ± 299 nmol/L, p=0.834) did not. There was a significant positive correlation between changes in ubiquinol and ApoA1 (r=0.518, p=0.005). Multivariate regression analysis showed that changes in ubiquinol correlated significantly with changes in ApoA1 after adjusting for age, sex, body mass index, and smoking (β=0.502, p=0.008).

CONCLUSIONS

Compared to atorvastatin, rosuvastatin combined with exercise significantly preserved ubiquinol levels associated with an increase in HDL-C. Rosuvastatin with regular exercise could be beneficial for CAD patients.

摘要

背景

辅酶 Q10 水平在冠状动脉疾病(CAD)患者中较低,增加或保留辅酶 Q10 可能是一种有益的策略。运动和他汀类药物可提高高密度脂蛋白胆固醇(HDL-C)水平。然而,他汀类药物抑制辅酶 Q10 的生物合成,与他汀类药物单独使用相比,他汀类药物与辅酶 Q10 补充剂的联合使用可增加 HDL-C。我们比较了两种他汀类药物(瑞舒伐他汀和阿托伐他汀)联合运动对 CAD 患者辅酶 Q10 和 HDL-C 水平的影响。

方法

将 28 例 CAD 患者随机分为瑞舒伐他汀(n=14)和阿托伐他汀(n=14)组后,患者每周在医院进行有氧运动,每天在家进行运动,共 20 周。我们测量了血清脂质、泛醇和运动能力。

结果

两种他汀类药物均同等程度地提高了运动能力,并降低了低密度脂蛋白胆固醇和甘油三酯水平。瑞舒伐他汀可显著增加 HDL-C(瑞舒伐他汀,+12±9mg/dL[+30%],阿托伐他汀,+5±5mg/dL[+13%],p=0.014)和载脂蛋白 A1(ApoA1)(瑞舒伐他汀,+28.3±20.7mg/dL,阿托伐他汀,+13.4±12.0mg/dL,p=0.030),而阿托伐他汀则没有。阿托伐他汀可显著降低血清泛醇(731±238 至 547±219nmol/L,p=0.001),但瑞舒伐他汀(680±233 至 668±299nmol/L,p=0.834)则没有。泛醇与 ApoA1 的变化呈显著正相关(r=0.518,p=0.005)。多元回归分析显示,在调整年龄、性别、体重指数和吸烟因素后,泛醇的变化与 ApoA1 的变化显著相关(β=0.502,p=0.008)。

结论

与阿托伐他汀相比,瑞舒伐他汀联合运动可显著保留与 HDL-C 增加相关的泛醇水平。瑞舒伐他汀结合规律运动可能对 CAD 患者有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验